BACKGROUND: Danon disease is an X-linked dominant disorder characterized by the clinical triad of hypertrophic cardiomyopathy, skeletal myopathy, and variable mental retardation. Pathologically, autophagic vacuoles are noted in both skeletal and cardiac muscle. It exhibits an X-linked dominant mode of inheritance, and male carriers are severely affected, whereas female carriers develop milder and later-onset cardiac symptoms. Danon disease has been associated with mutations in the lysosome-associated membrane glycoprotein 2 (LAMP2) gene located at Xq24, typically resulting in splicing defects or protein truncation affecting the LAMP2. Because of its rarity, the full spectrum of genetic mutation resulting in Danon disease has not been elucidated. METHODS AND RESULTS: We analyzed 3 male cases with clinical and pathological findings consistent with Danon disease. Comprehensive mutational analysis failed to yield detectable products for selected LAMP2 exons, and genomic DNA deletion was suspected. Genomic junction fragment polymerase chain reaction analysis in case 1 identified a novel Alu-mediated 34-kb microdeletion encompassing the entire 5'-untranslated region and exon 1 of LAMP2. In case 2 and 3, junctional polymerase chain reaction and Southern blot analyses mapped the breakpoint to an MIRb and (TA)(n) simple repeats present in intron 3, which determined a 64-kb and a 58-kb deletion, respectively, thereby ablating exons 4 to 10. Western blot analysis confirmed the absence of LAMP2 in protein extract from lymphocytes of index case 2. CONCLUSIONS: This article is the first report of Danon disease caused by microdeletions at Xq24, which functionally ablate LAMP2. The microdeletion mechanism appears to involve 1 Alu-mediated unequal recombination and 2 chromosomal breakage points involving TA-rich repeat sequences.
BACKGROUND: Danon disease is an X-linked dominant disorder characterized by the clinical triad of hypertrophic cardiomyopathy, skeletal myopathy, and variable mental retardation. Pathologically, autophagic vacuoles are noted in both skeletal and cardiac muscle. It exhibits an X-linked dominant mode of inheritance, and male carriers are severely affected, whereas female carriers develop milder and later-onset cardiac symptoms. Danon disease has been associated with mutations in the lysosome-associated membrane glycoprotein 2 (LAMP2) gene located at Xq24, typically resulting in splicing defects or protein truncation affecting the LAMP2. Because of its rarity, the full spectrum of genetic mutation resulting in Danon disease has not been elucidated. METHODS AND RESULTS: We analyzed 3 male cases with clinical and pathological findings consistent with Danon disease. Comprehensive mutational analysis failed to yield detectable products for selected LAMP2 exons, and genomic DNA deletion was suspected. Genomic junction fragment polymerase chain reaction analysis in case 1 identified a novel Alu-mediated 34-kb microdeletion encompassing the entire 5'-untranslated region and exon 1 of LAMP2. In case 2 and 3, junctional polymerase chain reaction and Southern blot analyses mapped the breakpoint to an MIRb and (TA)(n) simple repeats present in intron 3, which determined a 64-kb and a 58-kb deletion, respectively, thereby ablating exons 4 to 10. Western blot analysis confirmed the absence of LAMP2 in protein extract from lymphocytes of index case 2. CONCLUSIONS: This article is the first report of Danon disease caused by microdeletions at Xq24, which functionally ablate LAMP2. The microdeletion mechanism appears to involve 1 Alu-mediated unequal recombination and 2 chromosomal breakage points involving TA-rich repeat sequences.
Authors: S Yu; M Mangelsdorf; D Hewett; L Hobson; E Baker; H J Eyre; N Lapsys; D Le Paslier; N A Doggett; G R Sutherland; R I Richards Journal: Cell Date: 1997-02-07 Impact factor: 41.582
Authors: Matteo Vatta; Sonny J Stetson; Alejandro Perez-Verdia; Mark L Entman; George P Noon; Guillermo Torre-Amione; Neil E Bowles; Jeffrey A Towbin Journal: Lancet Date: 2002-03-16 Impact factor: 79.321
Authors: M H Gollob; M S Green; A S Tang; T Gollob; A Karibe; A S Ali Hassan ; F Ahmad; R Lozado; G Shah; L Fananapazir; L L Bachinski; R Roberts; A S Hassan Journal: N Engl J Med Date: 2001-06-14 Impact factor: 91.245
Authors: Sara L Van Driest; Michele A Jaeger; Steve R Ommen; Melissa L Will; Bernard J Gersh; A Jamil Tajik; Michael J Ackerman Journal: J Am Coll Cardiol Date: 2004-08-04 Impact factor: 24.094
Authors: Matthew A Lines; Stacy Hewson; William Halliday; Peter J B Sabatini; Tracy Stockley; Anne I Dipchand; Sarah Bowdin; Komudi Siriwardena Journal: JIMD Rep Date: 2013-11-13
Authors: David N Cooper; Albino Bacolla; Claude Férec; Karen M Vasquez; Hildegard Kehrer-Sawatzki; Jian-Min Chen Journal: Hum Mutat Date: 2011-09-02 Impact factor: 4.878
Authors: Wim T J Aanhaanen; Bastiaan J D Boukens; Aleksander Sizarov; Vincent Wakker; Corrie de Gier-de Vries; Antoni C van Ginneken; Antoon F M Moorman; Ruben Coronel; Vincent M Christoffels Journal: J Clin Invest Date: 2011-01-25 Impact factor: 14.808
Authors: Filip Majer; Ondrej Pelak; Tomas Kalina; Hana Vlaskova; Lenka Dvorakova; Tomas Honzik; Tomas Palecek; Petr Kuchynka; Martin Masek; Jiri Zeman; Milan Elleder; Jakub Sikora Journal: J Inherit Metab Dis Date: 2013-05-29 Impact factor: 4.982
Authors: Ryan S D'souza; Cecilia Levandowski; Dobromir Slavov; Sharon L Graw; Larry A Allen; Eric Adler; Luisa Mestroni; Matthew R G Taylor Journal: Circ Heart Fail Date: 2014-09 Impact factor: 8.790
Authors: Ozge Ceyhan-Birsoy; Trevor J Pugh; Mark J Bowser; Elizabeth Hynes; Ashley L Frisella; Lisa M Mahanta; Matt S Lebo; Sami S Amr; Birgit H Funke Journal: Mol Genet Genomic Med Date: 2015-12-16 Impact factor: 2.183